Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world

BACKGROUND: To identify factors for starting biosimilar TNF inhibitors (TNFI) in patients with rheumatic diseases. METHODS AND FINDING: Using a national claims database, we identified patients with rheumatoid arthritis (RA) or ankylosing spondylitis (AS) who had used TNFIs since they were approved i...

Descripción completa

Detalles Bibliográficos
Autores principales: Sung, Yoon-Kyoung, Jung, Sun-Young, Kim, Hyoungyoung, Choi, Seongmi, Im, Seul Gi, Lee, Yu Sang, Jang, Eun Jin, Cho, Soo-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980538/
https://www.ncbi.nlm.nih.gov/pubmed/31978121
http://dx.doi.org/10.1371/journal.pone.0227960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6980538/
https://www.ncbi.nlm.nih.gov/pubmed/31978121
http://dx.doi.org/10.1371/journal.pone.0227960

Ejemplares similares